At least four drugs approved in 2012 - Jakafi ruxolitinib, Kalydeco ivacaftor, Stribild elvitegravir/cobicistat/emtricitabine/tenofovir and Xtandi enzalutamide - are on track to post 2013 sales exceeding $350 million. Below are selected drugs approved in 2012 for which sales are disclosed. One drug from a biotech approved in 2013 is already expected to exceed $500 million in annual sales: Tecfidera dimethyl fumarate, which was approved for multiple sclerosis last March (see "Top Biotech Products"). (A) 2012 approval and nine-month sales in 2013 unless otherwise noted; (B) U.S. sales reported by Onyx Pharmaceuticals Inc., which Amgen Inc. (NASDAQ:AMGN) acquired in October 2013; Sales figures in millions; Sources: BCIQ: BioCentury Online Intelligence, company documents




2012 approval (A)

9-mo sales in 2013 (A)

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Juxtapid lomitapide

Homozygous familial hypercholesterolemia (hoFH)



Alimera Sciences Inc. (NASDAQ:ALIM)/pSivida Corp. (NASDAQ:PSDV; ASX:PVA)

Iluvien fluocinolone acetonide

Chronic diabetic macular edema (DME)


$0.9 (launched April-May 2013)

Almirall S.A. (Madrid:ALM)/Forest Laboratories Inc. (NYSE:FRX)/Menarini Group/Quintiles Transnational Holdings Inc. (NYSE:Q)

Tudorza Pressair aclidinium bromide (Bretaris/Eklira Genuair - EU)

Chronic obstructive pulmonary disease (COPD)


€60.9 ($82.3) (worldwide sales reported by Almirall); $43.4 (U.S. sales reported by Forest)